PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28941798-10 2017 Interestingly, shikonin presented an atypical kinetic inhibition of CYP3A2-mediated midazolam 1-hydroxylation in rats. Midazolam 84-93 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 68-74 28253826-8 2017 This result indicates that the 14 day-intragastric administration of codeine may inhibit the metabolism of bupropion (CYP2B1) and midazolam (CYP3A2) in rat. Midazolam 130-139 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 141-147 19255942-3 2009 In the liver there was a significant enhancement of the hydroxylation of midazolam in the microsomes and expression of cytochrome P450 (CYP) 3A1 messenger RNA (mRNA) and CYP3A2 mRNA. Midazolam 73-82 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 170-176 22067624-14 2012 CONCLUSIONS: Mild hypothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest through alterations in cytochrome P450 3a2 metabolic capacity rather than enzyme affinity as observed with other cytochrome P450s. Midazolam 78-87 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 140-159 21474682-4 2011 The evaluation of metabolic rate using recombinant P450s suggested that CYP3A2 and CYP2C11 contributed to 89 and 11% of MDZ metabolism, respectively. Midazolam 120-123 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 72-78 26037413-2 2015 Rat primary hepatocytes were incubated with midazolam (which is metabolized mainly by CYP3A2) at 37, 32 or 28 C. The Michaelis-Menten constant (Km) and maximum velocity (Vmax) of midazolam were estimated using the Michaelis-Menten equation. Midazolam 44-53 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 86-92 26037413-3 2015 The Km of CYP3A2 midazolam remained unchanged, but the Vmax decreased at 28 C. In rats, whose temperature was maintained at 37, 32 or 28 C by a heat lamp or ice pack, the plasma concentrations of midazolam were higher, whereas those in the brain and liver were unchanged at 28 C. The tissue/plasma concentration ratios were, however, increased significantly. Midazolam 17-26 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 10-16 26037413-3 2015 The Km of CYP3A2 midazolam remained unchanged, but the Vmax decreased at 28 C. In rats, whose temperature was maintained at 37, 32 or 28 C by a heat lamp or ice pack, the plasma concentrations of midazolam were higher, whereas those in the brain and liver were unchanged at 28 C. The tissue/plasma concentration ratios were, however, increased significantly. Midazolam 198-207 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 10-16 26037413-4 2015 The unbound fraction of midazolam in serum at 28 C was half that at 37 C. These pharmacokinetic changes associated with hypothermic conditions were due to reductions in CYP3A2 activity and protein binding. Midazolam 24-33 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 171-177 25430017-0 2015 Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Midazolam 65-74 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 92-98 25430017-10 2015 These results indicate that menthol enhanced the elimination clearance of midazolam by inducing hepatic CYP3A2 and that careful attention should be paid when menthol is ingested in combination with drugs that act as substrates for CYP3A. Midazolam 74-83 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 104-110 16891075-2 2006 A significant decrease (65%) of CYP3A2-related activity (midazolam oxidation) was observed in all senescent rats. Midazolam 57-66 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 32-38 18809653-3 2008 In addition, to assess the effects on CYP3A2 activities, the pharmacokinetics of midazolam (CYP3A2 substrate) and 1-OH-midazolam (metabolite of midazolam) were investigated. Midazolam 81-90 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 92-98 16564546-4 2006 To evaluate in vivo the effect of PVL on hepatic drug metabolism, the narcotic activity (sleep time) of midazolam, a specific substrate for CYP3A2, was measured. Midazolam 104-113 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 140-146 8886602-11 1996 Immunoinhibition studies revealed that polyclonal anti-rat CYP3A2 antibody inhibited MDZ metabolism 80-90% in rat, human, and cDNA-expressed human CYP3A4 microsomes, thus suggesting that members of the CYP3A4 subfamily were involved in the metabolism. Midazolam 85-88 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 59-65 8531135-4 1995 Midazolam (MZ) sleep times were used as CYP3A2-specific in vivo marker in male Sprague-Dawley rats. Midazolam 0-9 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 40-46 16125735-3 2005 The substrates used in this study were tolbutamide (CYP2C6), dextromethorphan (CYP2D2) and midazolam (CYP3A2). Midazolam 91-100 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 102-108 15988118-2 2005 Here we show that the amount of CYP3A2 in CCl(4)-treated rats can be estimated appropriately by applying the PKCYP test using midazolam (MDZ) as a probe, assuming that the qg value in control rats does not change. Midazolam 126-135 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 32-38 15988118-2 2005 Here we show that the amount of CYP3A2 in CCl(4)-treated rats can be estimated appropriately by applying the PKCYP test using midazolam (MDZ) as a probe, assuming that the qg value in control rats does not change. Midazolam 137-140 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 32-38 15988118-5 2005 The qg value of MDZ was determined in control rats and used to estimate the amounts of CYP3A2 in CCl4-treated rats; the result agreed well with the observed values. Midazolam 16-19 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 87-93 15988118-6 2005 The qg value of CYP3A2 estimated with MDZ as a probe was used together with our previously reported value for CYP1A2 (theophylline metabolism in the liver is known to be almost entirely mediated by CYP3A2 and CYP1A2) to predict the total body clearance (CL(tot)) of theophylline in CCl4-treated rats. Midazolam 38-41 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 16-22 15988118-9 2005 Thus, the PKCYP test using MDZ as a probe can be used to predict the amount of CYP3A2 and the CL(tot) of theophylline in CCl4-treated rats. Midazolam 27-30 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 79-85 12167482-9 2002 These results suggest that: (1) CYP3A1 protein is constitutive and largely expressed in rat liver slices; (2) regioselective midazolam oxidation appears to be mainly CYP3A2 dependent; and (3) since CYP3A isoforms have similar half-lives (about 10-14hr), the loss of CYP3A2 protein at 37 degrees might be due to a selective targeting (phosphorylation ?) Midazolam 125-134 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 166-172